Nottingham University Hospitals

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Stroke2 trials
• ANCA-associated vasculitis1 trial
• Bladder cancer1 trial
• Cerebral palsy1 trial
• Childhood cancers1 trial
• COPD1 trial
• Cystic fibrosis1 trial
• Iron deficiency anaemia1 trial
• Lung cancer1 trial
• Macular degeneration1 trial
• Metastatic breast cancer1 trial
• Myeloproliferative neoplasms1 trial
• and 1 more

Phase

• Phase 37 trials
• Phase 22 trials
• Phase 11 trial

Status

• Active, not recruiting5 trials
• Completed5 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Incyte Corporation2 trials
• Allarity Therapeutics1 trial
• Craig Anderson1 trial
• Daiichi Sankyo1 trial
• Imperial College London1 trial
• and 10 more

Running trials

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Not yet recruiting

  Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability

  NCT06134401· Imperial College London· Source

  Contact: Natalia G Souza

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

  NCT06237335· Phase 2· ReCode Therapeutics· Source

• Recruiting

  Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery

  NCT06977698· University of Nottingham· Source

  Contact: Nehal F Y Atallah, PhD

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

  NCT05215340· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

  NCT04663750· Phase 3· King's College Hospital NHS Trust· Source

  Contact: Alexander Foss (principal investigator)

• Active, not recruiting

  BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

  NCT06462001· Phase 3· Nottingham University Hospitals NHS Trust· Source

• Active, not recruiting

  Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.

  NCT03317990· University College, London· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cerebral palsy1 recruiting
• Childhood cancers1 recruiting
• Macular degeneration1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

  NCT05126901· Phase 3· Shield Therapeutics· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Terminated

  Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

  NCT04796324· Phase 2· Allarity Therapeutics· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Pulmonx Corporation· Source

• Completed

  Psychological Impact of COVID-19 on Intensive Care Survivors

  NCT05092529· Royal Liverpool University Hospital· Source

• Completed

  Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

  NCT02108860· Phase 3· University of South Florida· Source